# To Evaluate Dose and Safety of NanoEcho Particle-1 Using NanoEcho Imaging Device Examinations of Rectal Lymph Nodes in Healthy Volunteers and Rectal Cancer Patients.

Source: https://onco.cc/trials/nct06693375/  
OnCo record `nct06693375` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Iron oxide nanoparticles in colorectal cancer, run by NanoEcho AB, now recruiting.

## Summary

To Evaluate Dose and Safety of NanoEcho Particle-1 Using NanoEcho Imaging Device Examinations of Rectal Lymph Nodes in Healthy Volunteers and Rectal Cancer Patients. is a phase 2 interventional study registered as NCT06693375 by NanoEcho AB, with 12 participants planned, started 2024-10-29 and due to reach its primary completion in 2026-05. Interventions recorded: Iron oxide nanoparticles and Rectal Magnetomotoric ultrasound (MMUS).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06693375
- Phase: 2
- Setting: A Phase 2a, Exploratory, Two-Part, Open-Label Trial to Evaluate Dose and Safety of NanoEcho Particle-1 (Ferumoxtran) Using NanoEcho Imaging Device Examinations of Rectal Lymph Nodes in Healthy Volunteers, Part A, and Rectal Cancer Patients, Part B.
- Sponsor: NanoEcho AB
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT06693375: https://clinicaltrials.gov/study/NCT06693375

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)

---
JSON: https://onco.cc/api/v1/entities/nct06693375.json